Skip to content

Risk Stratification Value of Biomarkers in Patients With Myocarditis

Risk Stratification Value of Biomarkers in Patients With Myocarditis (FORWARD): a National, Multicenter, Retrospective-prospective, Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06010199
Acronym
FORWARD
Enrollment
1000
Registered
2023-08-24
Start date
2023-08-25
Completion date
2030-08-31
Last updated
2024-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocarditis

Keywords

Myocarditis, Biomarker, Risk stratification

Brief summary

The aim of this study is to collect clinical data and biological specimens from patients with myocarditis and construct a predictive model for the prognosis of myocarditis.

Detailed description

The aim of this study is to retrospectively and prospectively collect clinical data and biological specimens from patients with myocarditis who meet the inclusion and exclusion criteria. General molecular biology analysis, genome sequencing, transcriptome sequencing, methylation sequencing, metabolomics analysis, proteomics analysis, genome-wide chromosome conformation capture and other techniques are used to construct a prognosis prediction model for myocarditis.

Interventions

None listed

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
3 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* All patients should meet the diagnostic criteria for myocarditis * Patients who are regularly followed up at the corresponding cardiovascular center

Exclusion criteria

* Age \<3 years or \>80 years * Pregnant or lactating women * The patient refused to sign the informed consent and refused to participate in the study * None of the above is consistent, but the patient cannot sign the informed consent temporarily due to coma and other reasons, and there is no legal representative to sign it instead. Depending on the condition, the patient may not wake up to sign the informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change in the incidence of MACCE1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.MACE (major adverse cardiovascular events) including all-cause death, myocardial infarction, stroke and coronary revascularization surgery. The MACCE will be assessed from the medical records.

Secondary

MeasureTime frameDescription
Change in the incidence of all-cause death1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.All-cause death diagnosed by clinical doctors will be assessed from the medical records
Change in the incidence of myocardial infarction1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.Myocardial infarction diagnosed by clinical doctors will be assessed from the medical records
Change in the incidence of stroke1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.Stroke diagnosed by clinical doctors will be assessed from the medical records
Change in the incidence of coronary revascularization surgery1, 3, 6 months after enrollment; and 1, 2, 3, 4, 5 years after enrollment.Coronary revascularization surgery completed by clinical doctors will be assessed from the medical records

Countries

China

Contacts

Primary ContactGuoliang Li
liguoliang_med@163.com+8613759982523
Backup ContactYang Yan
yangyan3@xjtu.edu.cn+8613259882601

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026